постановление правительства рф от 29 июня 1995 г 647
Главное меню:
Интересное
постановление правительства рф от 29 июня 1995 г 647, XTANDI® (enzalutamide) Dosing & Prescribing Info | HCP Site, XTANDI (enzalutamide) capsules - Food and Drug Administration, XTANDI® (enzalutamide) for mCSPC, nmCRPC & mCRPC | HCP Site, XTANDI® (enzalutamide) Downloadable Resources, HIGHLIGHTS OF PRESCRIBING INFORMATION ----------------------- WARNINGS , Evolent Clinical Guideline 3024 for XtandiTM (enzalutamide), TALZENNA® (talazoparib) + XTANDI® (enzalutamide) | Safety Info.
Seizure occurred in 0.6% of patients receiving XTANDI in eight randomized clinical trials. In a study of patients with predisposing factors for seizure, 2.2% of XTANDI-treated patients experienced a seizure. It is unknown whether anti-epileptic medications will prevent seizures with XTANDI. Patients in the study had one or more of the following predisposing factors: use of medications that may lower the seizure threshold, history of traumatic brain or head injury, history of cerebrovascular accident or transient ischemic attack, and Alzheimer’s disease, meningioma, or leptomeningeal disease from prostate cancer, unexplained loss of consciousness within the last 12 months, history of seizure, presence of a space occupying lesion of the brain, history of arteriovenous malformation, or history of brain infection. Advise patients of the risk of developing a seizure while taking XTANDI and of engaging in any activity where sudden loss of consciousness could cause serious harm to themselves or others. Permanently discontinue XTANDI in patients who develop a seizure during treatment., Find downloadable documents for healthcare professionals about XTANDI® (enzalutamide) tablets including dosing information and prescribing information., HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use XTANDI® safely and effectively. See full prescribing information for XTANDI. XTANDI® (enzalutamide) capsules, for oral use Initial U.S. Approval: 2012.
See the risks and benefits of XTANDI® (enzalutamide) for the treatment of patients with mCSPC, nmCRPC, and mCRPC., Find resources to help you stay on track with your treatment, like the XTANDI Support Solutions Pamphlet, Prescribing Information, and more. See Important Safety Info, Risks, and Benefits., HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use XTANDI safely and effectively. See full prescribing information for XTANDI. for oral use XTANDI® (enzalutamide) tab --- and, Members receiving Xtandi (enzalutamide) for nmCSPC may be treated with or without a GnRH analog concurrently. Xtandi (enzalutamide) may be used with Talzenna (talazoparib) for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) with the exception of BRCA 1 and 2 mutation positive mCRPC., Learn more about TALZENNA and XTANDI, an Rx treatment that can be used to treat adults with HRR gene-mutated mCRPC (prostate cancer). See risks and benefits., Capsules: XTANDI® (enzalutamide) was approved by the Food and Drug Administration (FDA) for the treatment of a type of prostate cancer that: no longer responds to a medical or surgical treatment that lowers testosterone, and has spread, or metastasized, beyond the prostate to other parts of the body.1.